Icade Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Icade de 86.7% y 1.6% por año respectivamente. Se prevé que el BPA crezca en un 94.6% al año. Se espera que la rentabilidad financiera sea de 5.6% en 3 años.
Información clave
86.7%
Tasa de crecimiento de los beneficios
94.65%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de REITs | 11.5% |
| Tasa de crecimiento de los ingresos | 1.6% |
| Rentabilidad financiera futura | 5.60% |
| Cobertura de analistas | Good |
| Última actualización | 06 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.
ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?
If you want to know who really controls Icade SA ( EPA:ICAD ), then you'll have to look at the makeup of its share...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 1,409 | 244 | 111 | 181 | 4 |
| 12/31/2027 | 1,328 | 154 | 831 | 208 | 5 |
| 12/31/2026 | 1,304 | 47 | 962 | 253 | 5 |
| 12/31/2025 | 1,337 | -123 | 300 | 300 | N/A |
| 9/30/2025 | 1,338 | -155 | 314 | 314 | N/A |
| 6/30/2025 | 1,339 | -187 | 328 | 328 | N/A |
| 3/31/2025 | 1,376 | -231 | 347 | 347 | N/A |
| 12/31/2024 | 1,412 | -275 | 366 | 366 | N/A |
| 9/30/2024 | 1,468 | -614 | 316 | 316 | N/A |
| 6/30/2024 | 1,523 | -953 | 265 | 265 | N/A |
| 3/31/2024 | 1,524 | -1,121 | 251 | 251 | N/A |
| 12/31/2023 | 1,525 | -1,289 | 238 | 238 | N/A |
| 9/30/2023 | 1,494 | -1,116 | 317 | 317 | N/A |
| 6/30/2023 | 1,464 | -944 | 397 | 397 | N/A |
| 3/31/2023 | 1,467 | -657 | 319 | 319 | N/A |
| 12/31/2022 | 1,469 | -370 | 242 | 242 | N/A |
| 9/30/2022 | 1,496 | -61 | N/A | N/A | N/A |
| 6/30/2022 | 1,524 | 249 | 547 | 224 | N/A |
| 3/31/2022 | 1,586 | 324 | 538 | 377 | N/A |
| 12/31/2021 | 1,648 | 399 | 529 | 529 | N/A |
| 6/30/2021 | 1,640 | 280 | -51 | 600 | N/A |
| 3/31/2021 | 1,534 | 178 | 34 | 625 | N/A |
| 12/31/2020 | 1,429 | 76 | 120 | 650 | N/A |
| 6/30/2020 | 1,458 | 259 | -233 | 453 | N/A |
| 3/31/2020 | 1,485 | 278 | -325 | 411 | N/A |
| 12/31/2019 | 1,512 | 298 | -417 | 369 | N/A |
| 9/30/2019 | 1,587 | 235 | N/A | 358 | N/A |
| 6/30/2019 | 1,662 | 173 | N/A | 346 | N/A |
| 3/31/2019 | 1,717 | 165 | N/A | 351 | N/A |
| 12/31/2018 | 1,773 | 156 | N/A | 356 | N/A |
| 9/30/2018 | 1,714 | 137 | N/A | 372 | N/A |
| 6/30/2018 | 1,655 | 118 | N/A | 387 | N/A |
| 3/31/2018 | 1,642 | 142 | N/A | 362 | N/A |
| 12/31/2017 | 1,629 | 165 | N/A | 337 | N/A |
| 6/30/2017 | 1,596 | 106 | N/A | 255 | N/A |
| 3/31/2017 | 1,542 | 75 | N/A | 235 | N/A |
| 12/31/2016 | 1,487 | 45 | N/A | 215 | N/A |
| 6/30/2016 | 1,391 | -101 | N/A | 309 | N/A |
| 3/31/2016 | 1,411 | -144 | N/A | 307 | N/A |
| 12/31/2015 | 1,431 | -187 | N/A | 305 | N/A |
| 6/30/2015 | 1,649 | 82 | N/A | 526 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que ICAD sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).
Beneficios vs. Mercado: Se prevé que ICAD sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que ICAD sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (1.6% al año) de ICAD crezcan más despacio que el mercado de French (5.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 1.6% al año) de ICAD crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ICAD sea baja dentro de 3 años (5.6%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 04:36 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Icade está cubierta por 21 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Celine Huynh | Barclays |